GlassScriptPhysician profile
Firas Muwalla
NPI 1013979566
$7,569.00
in general payments reported to CMS, 2019-2025
48 companies · $688 in 2025
The $688 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,292 · 2020: $1,004 · 2021: $1,628 · 2022: $1,003 · 2023: $192 · 2024: $761 · 2025: $688.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,630 · Education: $11.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,629.80 |
| Education | $11.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,189.63 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $652.40 | 2019-2025 | Augtyro, Opdivo, Camzyos |
| Pfizer INC. | $606.82 | 2019-2024 | |
| Daiichi Sankyo INC. | $451.83 | 2019-2025 | Enhertu |
| Astrazeneca Pharmaceuticals LP | $446.64 | 2019-2025 | |
| Janssen Biotech, INC. | $371.22 | 2019-2025 | Erleada, Akeega, Balversa |
| Merck Sharp & Dohme LLC | $348.27 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Glaxosmithkline, LLC. | $339.10 | 2021-2025 | Ojjaara |
| Amgen INC. | $334.66 | 2019-2023 | Lumakras |
| Seagen INC. | $279.02 | 2019-2022 | |
| Celgene Corporation | $260.68 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $180.14 | 2019-2021 | |
| Genzyme Corporation | $161.85 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $158.06 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $144.37 | 2020-2022 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Firas Muwalla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.